Since (a) NSC23766 is a small molecule inhibitor of TIAM1 activity (20), (b) IPA and CMap analysis supported TIAM1/RAC1 signaling as a possible pathway useful for the therapeutic targeting of BPH (Figure 2B), and (c) the BPH transcriptomic signature revealed TIAM1 upregulation in all 3 datasets, we sought to validate the increase of expression of TIAM1 in a fourth independent patient cohort. Here, TIAM1 is linked to benign prostatic hyperplasia.